2,10-dihydroxy-6-({[4-(hydroxymethyl)pyridin-2-yl]methyl}amino)-13-(β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione | 213039-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,10-dihydroxy-6-({[4-(hydroxymethyl)pyridin-2-yl]methyl}amino)-13-(β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
• 英文别名: 6,20-dihydroxy-13-[[4-(hydroxymethyl)pyridin-2-yl]methylamino]-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
• CAS: 213039-84-0
• 化学式: C₃₃H₂₉N₅O₁₀
• 分子量: 655.621
• InChiKey: WFDSUZQOPSRSMZ-CBUVUTGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  48
• 可旋转键数：
  6
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  234
• 氢给体数：
  9
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  2,10-dihydroxy-6-{[(1E)-[4-(hydroxymethyl)pyridin-2-yl]methylene]amino}-13-(β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 在 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 以51%的产率得到2,10-dihydroxy-6-({[4-(hydroxymethyl)pyridin-2-yl]methyl}amino)-13-(β-D-glucopyranosyl)-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
  参考文献：
  名称：

  Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-Arylmethylamino Analogues of Edotecarin

  摘要：

  The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. Furthermore, compounds 22m and 23c exhibited complete response against MX-1 cells implanted in mice.

  DOI：

  10.1021/jm801641t

文献信息

• Indolopyrrolocarbazole derivatives and antitumor agents
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06703373B1

  公开（公告）日：2004-03-09

  A compound represented by the formula or a pharmaceutically acceptable salt thereof wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient. The compounds have a better antitumor action than known compounds having a similar structure.

  化合物的化学式为或其药学上可接受的盐，其中R代表未取代的吡啶基，呋喃基或噻吩基，或者是带有一个或多个取代基的吡啶基，呋喃基或噻吩基，所述取代基选自羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团的群，但是当吡啶基，呋喃基或噻吩基带有较低的烷氧基取代基时，每个取代基同时具有羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团中的另一个取代基时，m表示1到3的整数，G表示β-D-葡萄糖吡喃糖基，并且羟基取代在吲哚吡咯喹啉环上的位置为1-和11-位置，或2-和10-位置，以及含有其作为有效成分的抗肿瘤剂。这些化合物比具有类似结构的已知化合物具有更好的抗肿瘤作用。
• Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-Arylmethylamino Analogues of Edotecarin
  作者：Satoshi Sunami、Teruyuki Nishimura、Ikuko Nishimura、Satoru Ito、Hiroharu Arakawa、Mitsuru Ohkubo

  DOI：10.1021/jm801641t

  日期：2009.5.28

  The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. Furthermore, compounds 22m and 23c exhibited complete response against MX-1 cells implanted in mice.